"Aminobutyrates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivatives of BUTYRIC ACID that contain one or more amino groups attached to the aliphatic structure. Included under this heading are a broad variety of acid forms, salts, esters, and amides that include the aminobutryrate structure.
Descriptor ID |
D000613
|
MeSH Number(s) |
D02.241.081.114.500 D12.125.190
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Aminobutyrates".
Below are MeSH descriptors whose meaning is more specific than "Aminobutyrates".
This graph shows the total number of publications written about "Aminobutyrates" by people in this website by year, and whether "Aminobutyrates" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2004 | 1 | 0 | 1 |
2016 | 1 | 0 | 1 |
2018 | 1 | 0 | 1 |
2019 | 1 | 0 | 1 |
2020 | 0 | 1 | 1 |
2021 | 0 | 1 | 1 |
2022 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aminobutyrates" by people in Profiles.
-
Gabot A, Lavitas P, Bacon R, Pomfret TC, Taylor M, Coelho A, Greenwood BC, Alper CJ, Clements KM, Lenz K. Cost-benefit analysis of sacubitril/valsartan in a Medicaid population. Am J Manag Care. 2022 07; 28(7):349-352.
-
Mann DL, Givertz MM, Vader JM, Starling RC, Shah P, McNulty SE, Anstrom KJ, Margulies KB, Kiernan MS, Mahr C, Gupta D, Redfield MM, Lala A, Lewis GD, DeVore AD, Desvigne-Nickens P, Hernandez AF, Braunwald E. Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA Cardiol. 2022 01 01; 7(1):17-25.
-
Kim YS, Brar S, D'Albo N, Dey A, Shah S, Ganatra S, Dani SS. Five Years of Sacubitril/Valsartan-a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance. Cardiovasc Drugs Ther. 2022 10; 36(5):915-924.
-
Dani SS, Ganatra S, Vaduganathan M. Angioedema with sacubitril/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date. Int J Cardiol. 2021 01 15; 323:188-191.
-
Maslov MY, Foianini S, Mayer D, Orlov MV, Lovich MA. Interaction Between Sacubitril and Valsartan in Preventing Heart Failure Induced by Aortic Valve Insufficiency in Rats. J Card Fail. 2019 Nov; 25(11):921-931.
-
Maslov MY, Foianini S, Mayer D, Orlov MV, Lovich MA. Synergy between sacubitril and valsartan leads to hemodynamic, antifibrotic, and exercise tolerance benefits in rats with preexisting heart failure. Am J Physiol Heart Circ Physiol. 2019 02 01; 316(2):H289-H297.
-
Lee DK, Youk H, Kim H, Kim OH, Go J, Kim TH, Cha K, Lee KH, Hwang SO, Cha YS. Initial Serum Ammonia as a Predictor of Neurologic Complications in Patients with Acute Glufosinate Poisoning. Yonsei Med J. 2016 Jan; 57(1):254-9.
-
Liu G, Dou S, He J, Vanderheyden JL, Rusckowski M, Hnatowich DJ. Preparation and properties of 99mTc(CO)3+-labeled N,N-bis(2-pyridylmethyl)-4-aminobutyric acid. Bioconjug Chem. 2004 Nov-Dec; 15(6):1441-6.